Peptide · Fact sheet

Ipamorelin

Also known as ipamorelin acetate

Ipamorelin is an experimental peptide that can stimulate growth-hormone release. It is not an FDA-approved medicine, and FDA has described important evidence gaps and potential safety concerns.

Not FDA approvedEarly human evidence

What is Ipamorelin?

Ipamorelin is a synthetic growth hormone secretagogue that acts at the ghrelin receptor.

It has been investigated in human research, including studies of gastrointestinal motility, but that does not establish common online claims.

Benefits & claims

It is promoted for muscle, recovery, sleep, fat loss, and anti-aging, often in combination with CJC-1295.

Combination marketing makes it harder to know which ingredient caused an effect or adverse event.

What the evidence supports

  • Studies confirm pharmacologic effects on hormone signaling.
  • Evidence does not yet establish a favorable benefit-risk profile for popular consumer uses.
Research areas
  • Growth hormone release
  • Gastrointestinal motility
  • Postoperative ileus
  • Growth-hormone and gastrointestinal pathway effects

Dosage & frequency

Human study context

The verified early human study used a single intravenous infusion to characterize hormone responses. It does not establish a subcutaneous wellness or recovery regimen.

Healthy-volunteer PK/PD study

Healthy male volunteers in ascending-dose cohorts

Amount
4.21–140.45 nmol/kg across separate cohorts
Frequency
One 15-minute study infusion
Route studied or labeled
Intravenous

Pharmacokinetic and GH-response study; not a repeated subcutaneous regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Terminal half-life in the IV study
Approximately two hours; route-specific research estimate.

Formulation differences

  • Research with a pharmaceutical study formulation cannot establish equivalence for other preparations.

Interactions & precautions

  • A single IV PK/PD experiment does not establish interactions during repeated subcutaneous use or with other endocrine treatments.

What is still unresolved

  • Clinical efficacy and a supported repeated-use subcutaneous schedule remain unestablished.

Side effects & risks

  • FDA describes potential immune reactions and complexities related to impurities and peptide characterization.
  • FDA notes serious adverse events, including deaths, in a study using intravenous ipamorelin for gastric motility; that context does not establish cause for every event but is a serious signal.
  • Safety information for other routes and long-term use is insufficient.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Human studies exist, but they do not provide strong evidence for the broad performance, recovery, or anti-aging outcomes promoted to consumers.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Positive account · personal report

Better energy and recovery with CJC-1295

A commenter described better energy, sleep, mood, concentration and gym recovery during combined ipamorelin and CJC-1295 use.

Reported use in this account

Product
Ipamorelin with CJC-1295
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Two reported three-month exposure periods

Other exposures described: CJC-1295

Neither the products nor outcomes were independently checked. The combination and ongoing training prevent isolating ipamorelin.

Read the original account
Mixed account · personal report

Easier sleep with daytime sleepiness and vivid dreams

A person using products labeled ipamorelin and CJC-1295 without DAC reported falling asleep easily, vivid dreams, lower motivation and unwanted daytime sleepiness.

Reported use in this account

Product
Ipamorelin with CJC-1295 described as without DAC
Amount
200 mcg of ipamorelin
Frequency
On five days per week; administrations per day not stated
Route
Injection; specific route not stated
Duration
Three weeks stated; another week number conflicts

Other exposures described: CJC-1295 described as without DAC

Combined exposure prevents attribution to ipamorelin. The accompanying product was labeled CJC-1295 without DAC, not the long-acting CJC-1295 studied in the cited clinical research.

Read the sleepiness report

Approval status

Ipamorelin is not FDA approved. FDA has described potential immunogenicity and impurity concerns and insufficient safety information for certain routes.

Mid-stage study completed without approval

Ipamorelin reached a Phase 2 postoperative-ileus study, but it has no FDA-approved product and the cited research does not support broad consumer wellness claims.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term safety and uncommon adverse effects
  • Meaningful benefits for body composition, recovery, sleep, or aging
  • Safety of combinations promoted online
  • Product identity, purity, and consistency outside approved manufacturing

Summary

Ipamorelin is unapproved and lacks strong human evidence for advertised recovery, muscle or anti-aging benefits.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: bulk substances that may present significant safety risks

    FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.

  2. clinical trialsClinicalTrials.gov: ipamorelin for postoperative ileus

    Registry record for an ipamorelin postoperative ileus study.

  3. pubmedIpamorelin pharmacokinetic-pharmacodynamic study

    Human pharmacology study characterizing ipamorelin exposure and growth-hormone responses.

  4. pubmedIpamorelin postoperative ileus proof-of-concept study

    Randomized proof-of-concept study of ipamorelin for postoperative ileus.

How we assess sources · Suggest a correction